Experience

Zepto Life Technology

• United States
• Biotechnology Research
• 1 - 100 Employee

• Founder and CEO

  • Mar 2014 - Present

  Since the inception of Zepto Life Technology in 2014, we have raised 20 million USD to build a highly talented team of scientists and engineers who have established a solid IP portfolio. We have also defined a clear regulatory pathway, developed strong clinical partnerships with the Mayo Clinic, and built our clean rooms and manufacturing facility. We are targeting the launch of our first product in 2020. Zepto Life’s first product is designed to measure D-Dimer and as an aid in the… Show more Since the inception of Zepto Life Technology in 2014, we have raised 20 million USD to build a highly talented team of scientists and engineers who have established a solid IP portfolio. We have also defined a clear regulatory pathway, developed strong clinical partnerships with the Mayo Clinic, and built our clean rooms and manufacturing facility. We are targeting the launch of our first product in 2020. Zepto Life’s first product is designed to measure D-Dimer and as an aid in the diagnosis of venous thromboembolism (VTE) and in the exclusion of deep vein thrombosis (DVT) and pulmonary embolism (PE). Its cardiac point-of-care handheld diagnostic system is designed to achieve: • Lab Quality Results at Point-of-Care • Simplicity and Versatility • Confidence and Trust in Product Quality Zepto Life Technology is on a mission to innovate and develop a highly-sensitive and multiplexed immunoassay and molecular diagnostics technology platform that can quickly diagnose diseases and determine medical interventions using a handheld device. The root of Zepto Life's technology was based on the giant magnetoresistance (GMR) principle, a 2007 Nobel Prize winner in Physics. The company licensed the GMR biosensing technology from the University of Minnesota. Headquartered in St. Paul, Minnesota, Zepto Life Technology became a privately-held company in 2014. Since 2014, Zepto Life Technology has been designing and developing its proprietary Gigantic Magneto-Resistance (GMR) biosensing chips, on-chip bio-surface technology, magnetic nanoparticle immunoassay, and microfluidic technology. The scientific and engineering has since built a solid intellectual property portfolio. The company is also conducting advanced development and research to potentially expand its protein biomarkers technology to include molecular diagnostics in its product portfolio. Show less Since the inception of Zepto Life Technology in 2014, we have raised 20 million USD to build a highly talented team of scientists and engineers who have established a solid IP portfolio. We have also defined a clear regulatory pathway, developed strong clinical partnerships with the Mayo Clinic, and built our clean rooms and manufacturing facility. We are targeting the launch of our first product in 2020. Zepto Life’s first product is designed to measure D-Dimer and as an aid in the… Show more Since the inception of Zepto Life Technology in 2014, we have raised 20 million USD to build a highly talented team of scientists and engineers who have established a solid IP portfolio. We have also defined a clear regulatory pathway, developed strong clinical partnerships with the Mayo Clinic, and built our clean rooms and manufacturing facility. We are targeting the launch of our first product in 2020. Zepto Life’s first product is designed to measure D-Dimer and as an aid in the diagnosis of venous thromboembolism (VTE) and in the exclusion of deep vein thrombosis (DVT) and pulmonary embolism (PE). Its cardiac point-of-care handheld diagnostic system is designed to achieve: • Lab Quality Results at Point-of-Care • Simplicity and Versatility • Confidence and Trust in Product Quality Zepto Life Technology is on a mission to innovate and develop a highly-sensitive and multiplexed immunoassay and molecular diagnostics technology platform that can quickly diagnose diseases and determine medical interventions using a handheld device. The root of Zepto Life's technology was based on the giant magnetoresistance (GMR) principle, a 2007 Nobel Prize winner in Physics. The company licensed the GMR biosensing technology from the University of Minnesota. Headquartered in St. Paul, Minnesota, Zepto Life Technology became a privately-held company in 2014. Since 2014, Zepto Life Technology has been designing and developing its proprietary Gigantic Magneto-Resistance (GMR) biosensing chips, on-chip bio-surface technology, magnetic nanoparticle immunoassay, and microfluidic technology. The scientific and engineering has since built a solid intellectual property portfolio. The company is also conducting advanced development and research to potentially expand its protein biomarkers technology to include molecular diagnostics in its product portfolio. Show less



Optical Business, China

• Beijing City, China

• Founder and CEO

  • Jan 2002 - Present

  Founded and expanded the optical business into Beijing, China. The company became one of the top 10 optical brands and manufacturer in China. Currently serves as a board of director. Founded and expanded the optical business into Beijing, China. The company became one of the top 10 optical brands and manufacturer in China. Currently serves as a board of director.



Optical Business, Russia

• Moscow, Russian Federation

• Founder and CEO

  • Jan 1996 - Dec 2006

  Founded an optical business in Moscow, Russia. The business designed, brand and manufactured optical glasses for the Russian market. Successfully established a global distribution network to market and distribute the in-house brands. Founded an optical business in Moscow, Russia. The business designed, brand and manufactured optical glasses for the Russian market. Successfully established a global distribution network to market and distribute the in-house brands.